title: [GlaxoSmithKline requires additional consideration of the national procurement of cancer vaccine: Procurement of HPV vaccine is not consistent with good scientific, ethical and moral practice].
authors.affiliation: GlaxoSmithKline AB. johan.o.thor@gsk.com
authors.forename: Johan
authors.initials: J
authors.lastname: Thor
authors.forename: Olav
authors.initials: O
authors.lastname: Flaten
mesh_terms: D003657:Decision Making; D004345:Drug Industry; D017754:Group Purchasing; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D053918:Papillomavirus Vaccines / Q000600:supply & distribution; D010819:Physician's Role; D055818:Public-Private Sector Partnerships; D013548:Sweden
chemical_list: D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18